60 Degrees Pharmaceuticals, Inc.

SXTP
$1.49 (- $0.01 - 0.67%)
Last updated: 2026-07-30 01:29 UTC
SXTP Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS83006G5009
CUSIP83006G500
Market Price1.49
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-18.29
Market Cap$7.0M
Book Value-1.25
Price to Book-0.55
Beta2.98
52w High24.0
52w Low1.36
Next Earnings DateN/A

60 Degrees Pharmaceuticals, Inc. trades under ticker SXTP on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US83006G5009, CUSIP 83006G500. Also searched as 60 Degrees Pharmaceuticals.

Related researchSXTP stock priceSXTP share price60 Degrees Pharmaceuticals stock60 Degrees Pharmaceuticals share price83006G500
About the Company
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Price History